Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma
Mesothelioma is a rare and aggressive malignancy with a poor prognosis. Without treatment, the median survival time ranges between six and nine months [1]. As the diagnosis usually is made at an advanced stage most patients are not eligible for surgery and designated for palliative systemic treatment [2]. Treatment in first-line with a combination of platinum and pemetrexed resulted in a median survival benefit of three months [3]. The addition of bevacizumab resulted in an additional survival benefit of nearly three months [4]. (Source: Lung Cancer)
Source: Lung Cancer - December 13, 2023 Category: Cancer & Oncology Authors: D.W. Dumoulin, L.H. Douma, M.M. Hofman, V. van der Noort, R. Cornelissen, C.J. de Gooijer, J.A. Burgers, J.G.J.V. Aerts Source Type: research
Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
Acquired anaplastic lymphoma kinase (ALK) mutation is the major resistant mechanism to ALK tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients. At present, treatment options after acquiring secondary ALK mutations are still limited. Here, we report on a patient with metastatic ALK-rearranged NSCLC who was sequentially treated with ALK TKIs, from crizotinib to lorlatinib, and developed rare acquired compound ALK mutations (L1196M and D1203N) that confer resistance to lorlatinib. Moreover, our report describes the clinical response of an NSCLC patient with these compound mutations to multiple ant...
Source: Frontiers in Pharmacology - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
CONCLUSIONS: High-dose pemetrexed appears tolerable and shows objective antitumor activity in patients with chordoma. Phase II studies of high-dose pemetrexed are warranted.PMID:38047868 | DOI:10.1158/1078-0432.CCR-23-2317 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - December 4, 2023 Category: Cancer & Oncology Authors: Santosh Kesari Naveed Wagle Jose A Carrillo Akanksha Sharma Minhdan Nguyen Judy Truong Jaya M Gill Raffi Nersesian Natsuko Nomura Elnaz Rahbarlayegh Garni Barkhoudarian Walavan Sivakumar Daniel F Kelly Howard Krauss Matias A Bustos Dave S B Hoon Lars Anke Source Type: research
Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
CONCLUSIONS: High-dose pemetrexed appears tolerable and shows objective antitumor activity in patients with chordoma. Phase II studies of high-dose pemetrexed are warranted.PMID:38047868 | DOI:10.1158/1078-0432.CCR-23-2317 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - December 4, 2023 Category: Cancer & Oncology Authors: Santosh Kesari Naveed Wagle Jose A Carrillo Akanksha Sharma Minhdan Nguyen Judy Truong Jaya M Gill Raffi Nersesian Natsuko Nomura Elnaz Rahbarlayegh Garni Barkhoudarian Walavan Sivakumar Daniel F Kelly Howard Krauss Matias A Bustos Dave S B Hoon Lars Anke Source Type: research
Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
CONCLUSIONS: High-dose pemetrexed appears tolerable and shows objective antitumor activity in patients with chordoma. Phase II studies of high-dose pemetrexed are warranted.PMID:38047868 | DOI:10.1158/1078-0432.CCR-23-2317 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - December 4, 2023 Category: Cancer & Oncology Authors: Santosh Kesari Naveed Wagle Jose A Carrillo Akanksha Sharma Minhdan Nguyen Judy Truong Jaya M Gill Raffi Nersesian Natsuko Nomura Elnaz Rahbarlayegh Garni Barkhoudarian Walavan Sivakumar Daniel F Kelly Howard Krauss Matias A Bustos Dave S B Hoon Lars Anke Source Type: research
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.PMID:38042525 | DOI:10.1200/JCO.23.02219 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - December 2, 2023 Category: Cancer & Oncology Authors: Pasi A J änne David Planchard Kunihiko Kobayashi Ying Cheng Chee Khoon Lee Natalia Valdiviezo Konstantin Laktionov Tsung-Ying Yang Yan Yu Terufumi Kato Liyan Jiang Busyamas Chewaskulyong Sarayut Lucien Geater Jean-Marc Maurel Carlos Rojas Toshiaki Takaha Source Type: research
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.PMID:38042525 | DOI:10.1200/JCO.23.02219 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - December 2, 2023 Category: Cancer & Oncology Authors: Pasi A J änne David Planchard Kunihiko Kobayashi Ying Cheng Chee Khoon Lee Natalia Valdiviezo Konstantin Laktionov Tsung-Ying Yang Yan Yu Terufumi Kato Liyan Jiang Busyamas Chewaskulyong Sarayut Lucien Geater Jean-Marc Maurel Carlos Rojas Toshiaki Takaha Source Type: research
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma
Oncologist. 2023 Nov 30:oyad310. doi: 10.1093/oncolo/oyad310. Online ahead of print.ABSTRACTHerein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of chemotherapy with cisplatin and pemetrexed, and a second line of immunotherapy with atezolizumab. Comprehensive genomic profiling by nex...
Source: The Oncologist - December 1, 2023 Category: Cancer & Oncology Authors: Marco Maria Germani Chiara Boccaccio Antonio Matrone Eleonora Molinaro Greta Al ì Mirella Giordano Rossella Elisei Gabriella Fontanini Chiara Cremolini Source Type: research
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma
Oncologist. 2023 Nov 30:oyad310. doi: 10.1093/oncolo/oyad310. Online ahead of print.ABSTRACTHerein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of chemotherapy with cisplatin and pemetrexed, and a second line of immunotherapy with atezolizumab. Comprehensive genomic profiling by nex...
Source: The Oncologist - December 1, 2023 Category: Cancer & Oncology Authors: Marco Maria Germani Chiara Boccaccio Antonio Matrone Eleonora Molinaro Greta Al ì Mirella Giordano Rossella Elisei Gabriella Fontanini Chiara Cremolini Source Type: research
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma
Oncologist. 2023 Nov 30:oyad310. doi: 10.1093/oncolo/oyad310. Online ahead of print.ABSTRACTHerein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of chemotherapy with cisplatin and pemetrexed, and a second line of immunotherapy with atezolizumab. Comprehensive genomic profiling by nex...
Source: The Oncologist - December 1, 2023 Category: Cancer & Oncology Authors: Marco Maria Germani Chiara Boccaccio Antonio Matrone Eleonora Molinaro Greta Al ì Mirella Giordano Rossella Elisei Gabriella Fontanini Chiara Cremolini Source Type: research
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
CONCLUSIONS: The treatment scenario of ALK-positive disease is dynamically evolving. Furthermore, not all FDA- and EMA-approved compounds are approved in Italy with the same indications. This influences therapeutic opportunities and increases the need for greater clinical expertise to help and guide treatment selection.PMID:37999149 | DOI:10.3390/curroncol30110729 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Cesare Gridelli Marcello Tiseo Diego Luigi Cortinovis Maria Rita Migliorino Vito Barbieri Paolo Bironzo Alessandra Bearz Ilaria Attili Filippo de Marinis Source Type: research
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
CONCLUSIONS: The treatment scenario of ALK-positive disease is dynamically evolving. Furthermore, not all FDA- and EMA-approved compounds are approved in Italy with the same indications. This influences therapeutic opportunities and increases the need for greater clinical expertise to help and guide treatment selection.PMID:37999149 | PMC:PMC10670405 | DOI:10.3390/curroncol30110729 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Cesare Gridelli Marcello Tiseo Diego Luigi Cortinovis Maria Rita Migliorino Vito Barbieri Paolo Bironzo Alessandra Bearz Ilaria Attili Filippo de Marinis Source Type: research
